Robert Geho is a co-founder and CEO of Diasome Pharmaceuticals, Inc., focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. In his role at Diasome, he leads the management and strategic direction of the Company’s targeted insulin therapies, novel Type 2 diabetes technology, and oral therapy for obesity. In addition to his responsibilities at Diasome, he is a co-founder and director of SDG, Inc., a nanotechnology therapeutics company that is an Equity Partner Company of the Cleveland Clinic Foundation in Cleveland, Ohio. Mr. Geho has led or co-led multiple rounds of financing for several biotechnology companies, and he has been a key participant in the formation of multiple life sciences focused companies. He received both his undergraduate degree and an MBA from Case Western Reserve University. Mr. Geho also serves as a member of the board of directors of the Diabetes Hands Foundation.
The Liver’s Role in Diabetes, presented by Christy Whitaker-Clarke
In 2011 Teachers College Columbia University launched its solely online Master of Science in Diabetes Education and Management program. This 36-credit inter-professional master’s program is offered to clinicians who are currently in or interested in the diabetes field. As part of a course requirement, students will present ‘Master Chats’ on a variety of topics they have chosen based on discussions taking place in the tudiabetes community. Master Chats will include a 10-15 presentation followed by a Q and A.